The meeting comes days after the drugmaker and its partner BioNTech SE announced plans to seek U.S. and European regulatory approval for a third dose of their COVID-19 shot amid the spread of variants and data they said showed heightened risk of infection six months after initial inoculation.
On Monday, Pfizer is scheduled to meet with representatives of the FDA, a company spokesperson said. The meeting was first reported by the Washington Post. Fauci, in several television interviews on Sunday, said U.S. health officials were not dismissing the possible future need for boosters -- especially as breakthrough infections among those who have been vaccinated have emerged -- but that more data is needed for any formal recommendation."There are studies being done now ongoing as we speak about looking at the feasibility about if and when we should be boosting people...
U.S. health officials are still struggling to get people in some areas to receive their initial inoculations as the highly contagious Delta variant has grown to be the nation's dominant strain, with COVID-19 cases rising mostly among the unvaccinated.
Lol.
Yea sure. At best this is called lobbying. At worst corruption
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: CTVNews - 🏆 1. / 99 Read more »